AKUMS Akums Drugs Q2 FY26 results (Jul–Sep 2025) and concall
Akums Drugs reported a challenging Q2 FY26 with revenue and EBITDA declines primarily due to API price downtrends and ramp-up costs for new facilities. Despite this, the domestic branded formulations segment showed robust growth, and the company made significant strides in international expansion with a new JV in Zambia and progress on a European CDMO contract. Management remains focused on long-term value creation and margin improvement initiatives.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 5.8%, net profit down 54.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 328 | 337 | 329 | 332 | 309 −6% |
| EBITDA | 43 | 34 | 18 | 44 | 17 −60% |
| Net profit | 50 | 41 | 28 | 45 | 23 −54% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
